Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

James Wells (NPI 1164509873)

Field	Value
Entity Type	Individual
Organization	James Wells
Address	222 E Medical Ln Ste 400
City	West Columbia
State	SC
ZIP	29169
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	November 1, 2006

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

JAMES WELLS is a Hematology & Oncology physician in West Columbia, SC with an NPI enumerated on 2006-11-01 (≈20 years ago). Lifetime Medicare revenue on file totals $3.2M and there is no Medicaid billing on file, indicating an effectively single‑payer footprint concentrated in Medicare.

Revenue is highly concentrated in a small set of oncology drugs: the precomputed top 3 Medicare codes by revenue account for 46.6% of this provider's total Medicare revenue. The single largest contributor is J9271 (pembrolizumab) with $760K (25.1% of Medicare revenue), followed by J9299 (nivolumab) at $376.3K (12.4%) and J0897 (denosumab) at $278.6K (9.2%).

The code mix is consistent with an outpatient infusion oncology practice that delivers immune checkpoint inhibitors and bone‑supportive therapy alongside diagnostic imaging and in‑office management. High revenue lines include J9271 and J9299 immunotherapies, J0897 denosumab for bone support, A9595 piflufolastat f-18 ($208.7K) for targeted PET imaging, plus E/M and chemotherapy administration codes such as 99214 ($68.3K) and 96413 ($53.8K), showing integrated clinical and procedural services.

Competitive standing varies by drug: J9271 (rank #447 of 1841, 75th percentile) and J9299 (rank #234 of 505, 54th percentile) are described as typical, unremarkable volumes nationally, indicating this provider participates at a common level for those checkpoint inhibitors. By contrast J0897 (rank #497 of 10057, 95th percentile) is labeled notably above typical national volume, signaling unusually high denosumab use relative to peers.

Several supportive and biosimilar agents are clear high-volume outliers in national comparisons: J9035 (bevacizumab) is listed as notably above typical (rank #39 of 1852, 98th percentile) with $85.1K revenue, and J2506 (pegfilgrastim) is notably above typical (rank #19 of 586, 97th percentile) with $83.8K revenue. In addition, commonly billed chemotherapy/visit codes such as 96413 (rank #510 of 7514, 93rd percentile) and 99214 (rank #24203 of 479517, 95th percentile) are also notably above typical, suggesting sustained infusion throughput and patient visit volume.

Other high-revenue biologics show a more modest presence: J9144 (daratumumab) generated $253.1K but ranks in the 37th percentile (typical), J9173 (durvalumab) produced $141.2K and ranks in the 13th percentile (typical), and J9312 (rituximab) produced $116.2K and ranks in the 15th percentile (typical). These placements indicate selective use of certain high-cost agents while not leading nationally across all monoclonal therapies.

Diagnostic imaging and PET utilization are material to the practice revenue mix: A9595 (piflufolastat f-18) generated $208.7K and ranks in the 78th percentile (typical), 78815 (PET/CT fusion) generated $107.4K and ranks in the 79th percentile (typical), and A9552 (FDG‑F18) generated $22.9K (73rd percentile). This pattern suggests either on‑site PET capability or close referral relationships that support targeted imaging as part of care pathways.

Operational signals point to high infusion center activity and routine lab workflows: J1439 shows 41.3K claims for $41.3K revenue (typical, 70th percentile), while frequent specimen and lab codes such as 36415 (1.8K claims, $12.6K, 99th percentile), 85025 (1.7K claims, $13.9K, 96th percentile) and 80048 (1.5K claims, $12K, 98th percentile) all rank very high nationally. Together these volumes are consistent with consistent outpatient infusion throughput and ancillary lab services supporting oncology care delivery.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

94 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	19,000	$40	$760K
J9299	Injection, nivolumab, 1 mg	15,680	$20	$376.3K
J0897	Injection, denosumab, 1 mg	15,480	$20	$278.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,840	$40	$253.1K
J9022	Injection, atezolizumab, 10 mg	3,660	$60	$234.2K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	440	$470	$208.7K
J9173	Injection, durvalumab, 10 mg	2,280	$60	$141.2K
J9312	Injection, rituximab, 10 mg	1,820	$60	$116.2K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	150	$720	$107.4K
J9035	Injection, bevacizumab, 10 mg	1,580	$50	$85K

Showing 1–10 of 94

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 94 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

James Wells — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

94 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	17	30	19,700	$40	$832K
J9299	8	10	15,760	$20	$432K
J9144	9	10	8,460	$40	$349.4K
J9173	5	10	3,050	$60	$275.9K
J9022	2	10	3,550	$60	$239.1K
J9312	18	20	2,340	$60	$193.7K
A9595	4	10	410	$460	$175.9K
J0897	20	250	2,400	$20	$91.2K
J3490	50	50	70	$510	$57.7K
J2506	1	10	740	$80	$55.9K

Showing 1–10 of 94

Related Providers

Other providers that share a Tax Identification Number (TIN) with James Wells, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lexington Health Inc	SC	General Acute Care Hospital	$0	$27.4M
Lexington County Health Services District Inc	SC	General Acute Care Hospital	$0	$19.2M
Lexington Health Inc	SC	Urgent Care Clinic/Center	$0	$8.7M
Lexington Health Inc	SC	Pediatric Adolescent Medicine Physician	$0	$5.7M
Lexington Health Inc	SC	Emergency Medicine Physician	$0	$4.2M
Lexington County Health Serv	SC	General Acute Care Hospital	$0	$4M
Steven Madden	SC	Hematology & Oncology Physician	$4M	$0
Lexington Health Inc	SC	Family Medicine Physician	$0	$4M
Lexington Health Inc	SC	Obstetrics & Gynecology Physician	$0	$3.5M
Vijaya Korrapati	SC	Hematology & Oncology Physician	$3.4M	$0

Nearby Providers

Other providers in the same ZIP code as James Wells, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Palmetto Infusion Services LLC	SC	Infusion Therapy Clinic/Center	$0	$93.6M
United Cerebral Palsy Of South Carolina, Inc	SC	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$15.7M
Palmetto Retina Center LLC	SC	Ophthalmology Physician	$0	$10.6M
Karen Park Family Dentistry, P.A.	SC	Dentist	$0	$4.2M
John Payne	SC	Ophthalmology Physician	$4M	$0
John Wells	SC	Ophthalmology Physician	$3.9M	$0
Lexington Treatment Specialists LLC	SC	Methadone Clinic	$76.7K	$3.6M
Perrie Ryan	SC	Hematology & Oncology Physician	$3.3M	$0
William Clark	SC	Ophthalmology Physician	$3.3M	$0
Asheesh Lal	SC	Hematology & Oncology Physician	$3.2M	$0

James Wells — Billing Profile & Reimbursement Data

Sign up for James Wells — Billing Profile & Reimbursement Data policy alerts

James Wells — Billing Profile & Reimbursement Data

Sign up for James Wells — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References